A newfangled exercising weight - loss drug has shown some promising results in mice , trigger hopes it could be developed for utilization in humans . We ’ve heard a peck aboutthese types of drugsrecently , but this one works very differently . It does n’t affect appetence or how much solid food you consume – alternatively , it play a joke on the body into thinking it ’s doing more example .

The drug is called SLU - PP-332 , and it was develop by a team based at the University of Florida . Back in March , they published apapershowing how the chemical compound place a radical of proteins called ERRs , which are boosted during use . The proteins are vital for the procedure of metabolic footpath in tissues like the muscle and heart , but until now scientist have fight to activate them using drugs .

After successfully demo that SLU - PP-332 heighten ERR activity in mice of average weight , permit them to run 45 percent further and for 70 pct longer than common , the team turn their care to testing the chemical compound in obese mice .

The resultant role of the novel sketch demonstrate that with twice - daily treatment , the mice lost 12 per centum of their body weight and gained 10 times less fatty than an untreated group – all this while eat the same amount of food and doing the same amount of strong-arm action .

“ This compound is fundamentally telling skeletal muscle to make the same changes you see during endurance grooming , ” explain lead researcher Thomas Burris in astatement . “ When you treat mouse with the drug , you could see that their whole body metabolic process turns to using fatty acids , which is very similar to what people use when they are fasting or exercising . And the animals start losing weight unit . ”

Appetite - crush drugs likeOzempicandWegovyhave strike headlines in recent calendar month . Both of these branded drug control the same participating factor , call semaglutide . A relatively raw drug , semaglutide is sometimes dictate to mass withtype 2 diabetesto help them manage their blood glucose levels , but has also been approve for use inweight management .

Like any drug , semaglutide can cause side consequence , most peculiarly digestive issues like stomach pain , nausea , and looseness . Developing other drugs that work in different elbow room could help increase the kitchen stove of options usable to patient role , maximise the chances of them happen a intervention that work for them .

The full potential of SLU - PP-332 is yet to be explored , but the squad hopes that it could pave the path for a handling that allow people to lose weight unit whilst keep muscleman mass . It could also be of benefit to older people , whose bodies typically respond less well toexercise , let them to reap more benefit from physical action .

The road to developing unexampled drugs is long , and although other physical exertion - mimicking drugs have been tested , none have yet made it to market . These findings in mouse are an early step in this journeying , but many will be watching with great interestingness to see where it lead .

The study is published in theJournal of Pharmacology and Experimental Therapeutics .